Long-term respiratory follow-up of ICU hospitalized COVID-19 patients: Prospective cohort study

Carlos Roberto Ribeiro Carvalho, Celina Almeida Lamas, Rodrigo Caruso Chate, João Marcos Salge, Marcio Valente Yamada Sawamura, André L P de Albuquerque, Carlos Toufen Junior, Daniel Mario Lima, Michelle Louvaes Garcia, Paula Gobi Scudeller, Cesar Higa Nomura, Marco Antonio Gutierrez, Bruno Guedes Baldi, HCFMUSP Covid-19 Study Group, Carlos Roberto Ribeiro Carvalho, Celina Almeida Lamas, Rodrigo Caruso Chate, João Marcos Salge, Marcio Valente Yamada Sawamura, André L P de Albuquerque, Carlos Toufen Junior, Daniel Mario Lima, Michelle Louvaes Garcia, Paula Gobi Scudeller, Cesar Higa Nomura, Marco Antonio Gutierrez, Bruno Guedes Baldi, HCFMUSP Covid-19 Study Group

Abstract

Background: Coronavirus disease (COVID-19) survivors exhibit multisystemic alterations after hospitalization. Little is known about long-term imaging and pulmonary function of hospitalized patients intensive care unit (ICU) who survive COVID-19. We aimed to investigate long-term consequences of COVID-19 on the respiratory system of patients discharged from hospital ICU and identify risk factors associated with chest computed tomography (CT) lesion severity.

Methods: A prospective cohort study of COVID-19 patients admitted to a tertiary hospital ICU in Brazil (March-August/2020), and followed-up six-twelve months after hospital admission. Initial assessment included: modified Medical Research Council dyspnea scale, SpO2 evaluation, forced vital capacity, and chest X-Ray. Patients with alterations in at least one of these examinations were eligible for CT and pulmonary function tests (PFTs) approximately 16 months after hospital admission. Primary outcome: CT lesion severity (fibrotic-like or non-fibrotic-like). Baseline clinical variables were used to build a machine learning model (ML) to predict the severity of CT lesion.

Results: In total, 326 patients (72%) were eligible for CT and PFTs. COVID-19 CT lesions were identified in 81.8% of patients, and half of them showed mild restrictive lung impairment and impaired lung diffusion capacity. Patients with COVID-19 CT findings were stratified into two categories of lesion severity: non-fibrotic-like (50.8%-ground-glass opacities/reticulations) and fibrotic-like (49.2%-traction bronchiectasis/architectural distortion). No association between CT feature severity and altered lung diffusion or functional restrictive/obstructive patterns was found. The ML detected that male sex, ICU and invasive mechanic ventilation (IMV) period, tracheostomy and vasoactive drug need during hospitalization were predictors of CT lesion severity(sensitivity,0.78±0.02;specificity,0.79±0.01;F1-score,0.78±0.02;positive predictive rate,0.78±0.02; accuracy,0.78±0.02; and area under the curve,0.83±0.01).

Conclusion: ICU hospitalization due to COVID-19 led to respiratory system alterations six-twelve months after hospital admission. Male sex and critical disease acute phase, characterized by a longer ICU and IMV period, and need for tracheostomy and vasoactive drugs, were risk factors for severe CT lesions six-twelve months after hospital admission.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright: © 2023 Ribeiro Carvalho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Figures

Fig 1. Study flow chart, showing how…
Fig 1. Study flow chart, showing how the COVID-19 survivors were selected to participate in this follow-up until the final numbers analyzed.

References

    1. WHO [Internet]. World Health Organization Coronavirus Disease (COVID-19) Dashboard;c2020 [cited 2020 September 25]. Available from: .
    1. Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al.. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163. doi: 10.1186/s12931-020-01429-6
    1. Liu C, Ye L, Xia R, Zheng X, Yuan C, Wang Z, et al.. Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City, Zhejiang, China. Ann Am Thorac Soc. 2020;17(10):1231–7. doi: 10.1513/AnnalsATS.202004-324OC
    1. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al.. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89–95. doi: 10.1016/j.cmi.2020.09.023
    1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. doi: 10.1038/s41591-021-01283-z
    1. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al.. More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis. Res Sq. 2021.
    1. Sisó-Almirall A, Brito-Zerón P, Conangla Ferrín L, Kostov B, Moragas Moreno A, Mestres J, et al.. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health. 2021;18(8). doi: 10.3390/ijerph18084350
    1. Tanni SE, Fabro AT, de Albuquerque A, Ferreira EVM, Verrastro CGY, Sawamura MVY, et al.. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021;15(6):791–803. doi: 10.1080/17476348.2021.1916472
    1. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al.. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Netw Open. 2021;4(1):e2036142. doi: 10.1001/jamanetworkopen.2020.36142
    1. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022. doi: 10.1038/s41591-022-01840-0
    1. Carvalho CRR, Chate RC, Sawamura MVY, Garcia ML, Lamas CA, Cardenas DAC, et al.. Chronic lung lesions in COVID-19 survivors: predictive clinical model. BMJ Open. 2022;12(6):e059110. doi: 10.1136/bmjopen-2021-059110
    1. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al.. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–32. doi: 10.1016/S0140-6736(20)32656-8
    1. Madotto F, McNicholas B, Rezoagli E, Pham T, Laffey JG, Bellani G, et al.. Death in hospital following ICU discharge: insights from the LUNG SAFE study. Crit Care. 2021;25(1):144. doi: 10.1186/s13054-021-03465-0
    1. Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al.. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8. doi: 10.1038/s41413-020-0084-5
    1. Ketai L, Paul NS, Wong KT. Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease. J Thorac Imaging. 2006;21(4):276–83. doi: 10.1097/01.rti.0000213581.14225.f1
    1. Toufen C, Costa EL, Hirota AS, Li HY, Amato MB, Carvalho CR. Follow-up after acute respiratory distress syndrome caused by influenza a (H1N1) virus infection. Clinics (Sao Paulo). 2011;66(6):933–7. doi: 10.1590/s1807-59322011000600002
    1. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al.. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348(8):683–93. doi: 10.1056/NEJMoa022450
    1. Ferreira JC, Ho YL, Besen BAMP, Malbouisson LMS, Taniguchi LU, Mendes PV, et al.. Protective ventilation and outcomes of critically ill patients with COVID-19: a cohort study. Ann Intensive Care. 2021;11(1):92. doi: 10.1186/s13613-021-00882-w
    1. Busatto GF, de Araújo AL, Duarte AJDS, Levin AS, Guedes BF, Kallas EG, et al.. Post-acute sequelae of SARS-CoV-2 infection (PASC): a protocol for a multidisciplinary prospective observational evaluation of a cohort of patients surviving hospitalisation in Sao Paulo, Brazil. BMJ Open. 2021;11(6):e051706. doi: 10.1136/bmjopen-2021-051706
    1. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al.. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021;299(1):E177–E86. doi: 10.1148/radiol.2021203153
    1. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. 1991;144(5):1202–18. doi: 10.1164/ajrccm/144.5.1202
    1. Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999;32(6):703–17. doi: 10.1590/s0100-879x1999000600006
    1. Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406. doi: 10.1590/s1806-37132007000400008
    1. Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999;32(6):729–37. doi: 10.1590/s0100-879x1999000600008
    1. Toufen Junior C, De Santis Santiago RR, Hirota AS, Carvalho ARS, Gomes S, Amato MBP, et al.. Driving pressure and long-term outcomes in moderate/severe acute respiratory distress syndrome. Ann Intensive Care. 2018;8(1):119. doi: 10.1186/s13613-018-0469-4
    1. Bellan M, Baricich A, Patrucco F, Zeppegno P, Gramaglia C, Balbo PE, et al.. Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. Sci Rep. 2021;11(1):22666. doi: 10.1038/s41598-021-01215-4
    1. Frija-Masson J, Debray MP, Boussouar S, Khalil A, Bancal C, Motiejunaite J, et al.. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. Respir Med. 2021;184:106435. doi: 10.1016/j.rmed.2021.106435
    1. Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al.. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401–9. doi: 10.1136/thx.2004.030205
    1. Fabbri L, Moss S, Khan FA, Chi W, Xia J, Robinson K, et al.. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2022. doi: 10.1136/thoraxjnl-2021-218275
    1. Fortini A, Rosso A, Cecchini P, Torrigiani A, Lo Forte A, Carrai P, et al.. One-year evolution of DLCO changes and respiratory symptoms in patients with post COVID-19 respiratory syndrome. Infection. 2022;50(2):513–7. doi: 10.1007/s15010-022-01755-5
    1. Han X, Fan Y, Alwalid O, Zhang X, Jia X, Zheng Y, et al.. Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19. Radiology. 2021:210972. doi: 10.1148/radiol.2021210972
    1. Luger AK, Sonnweber T, Gruber L, Schwabl C, Cima K, Tymoszuk P, et al.. Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD Study. Radiology. 2022:211670. doi: 10.1148/radiol.211670
    1. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al.. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747–54. doi: 10.1016/S2213-2600(21)00174-0
    1. Keszler M. Mechanical ventilation strategies. Semin Fetal Neonatal Med. 2017;22(4):267–74. doi: 10.1016/j.siny.2017.06.003
    1. Wolfe KS, Patel BK, MacKenzie EL, Giovanni SP, Pohlman AS, Churpek MM, et al.. Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients. Chest. 2018;154(4):781–7. doi: 10.1016/j.chest.2018.07.016
    1. Achkar M, Jamal O, Chaaban T. Post-COVID lung disease(s). Ann Thorac Med. 2022;17(3):137–44. doi: 10.4103/atm.atm_103_22
    1. Aul DR, Gates DJ, Draper DA, Dunleavy DA, Ruickbie DS, Meredith DH, et al.. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med. 2021;188:106602. doi: 10.1016/j.rmed.2021.106602
    1. d’Alessandro M, Bergantini L, Cameli P, Curatola G, Remediani L, Bennett D, et al.. Serial KL-6 measurements in COVID-19 patients. Intern Emerg Med. 2021;16(6):1541–5. doi: 10.1007/s11739-020-02614-7

Source: PubMed

3
Abonner